Ixabepilone

證據等級: L5

預測適應症: 10 個

Ixabepilone: From Metastatic Breast Cancer to Ewing Sarcoma

One-Sentence Summary

Ixabepilone is a semisynthetic epothilone B analog and non-taxane microtubule-stabilizing agent, FDA-approved for the treatment of metastatic breast cancer. The TxGNN model predicts it may be effective for Ewing Sarcoma (score: 99.76%), with 2 clinical trials and 1 direct clinical publication currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Metastatic breast cancer (FDA-approved; not registered in India)
Predicted New Indication	Ewing Sarcoma
TxGNN Prediction Score	99.76%
Evidence Level	L2
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on published literature, Ixabepilone is an epothilone B analog that stabilizes microtubules by binding to β-tubulin, preventing depolymerization. This arrests dividing tumor cells in the G2/M phase and triggers apoptosis. A key advantage over taxanes is its reduced susceptibility to P-glycoprotein (MDR1)–mediated multidrug resistance, allowing activity in taxane-resistant tumors.

Ewing sarcoma is an aggressive pediatric bone and soft tissue malignancy driven by the EWS-FLI1 fusion oncogene. These highly proliferative tumor cells depend heavily on intact mitotic spindle function, and the characteristically low P-glycoprotein expression in Ewing sarcoma cells makes them particularly vulnerable to epothilone-class agents. Preclinical data from pediatric tumor xenograft models have confirmed sensitivity to ixabepilone even in paclitaxel-resistant settings, providing a strong mechanistic foundation for this prediction.

The Children’s Oncology Group (COG) directly tested this hypothesis: the completed Phase II trial NCT00331643 specifically enrolled children and young adults with refractory solid tumors including Ewing sarcoma, and published results in 2010. This clinical validation closely aligns with the TxGNN model’s top-ranked prediction and significantly elevates the credibility of this repurposing direction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00331643	Phase 2	Completed	120	COG Phase II trial evaluating ixabepilone in six solid tumor strata in children and young adults with refractory tumors (including Ewing sarcoma); results published as PMID 20068084; primary DLT was neutropenia
NCT00030108	Phase 1	Completed	30	Pediatric Phase I PK and dose-escalation study in refractory solid tumors and leukemias; established the maximum tolerated dose of 8 mg/m²/dose in children and defined the safe dosing schedule used in the Phase II trial

Literature Evidence

PMID	Year	Type	Journal	Key Findings
20068084	2010	Phase II Clinical Trial	Clinical Cancer Research	Ixabepilone (daily × 5 days IV schedule) evaluated in six pediatric solid tumor strata including Ewing sarcoma; microtubule-stabilizing activity demonstrated against paclitaxel-resistant pediatric xenograft models; primary DLT was neutropenia; provides the core clinical efficacy and safety data for this repurposing direction

India Market Information

Ixabepilone currently has no registered products in India (0 licenses). The drug is not approved or marketed locally. Any clinical use would require an import license or Investigational New Drug (IND) application through CDSCO.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Epothilone class (non-taxane microtubule-stabilizing agent)
Myelosuppression Risk	High — neutropenia is the primary dose-limiting toxicity; thrombocytopenia also reported across Phase I–III studies
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential (ANC monitoring mandatory), liver function tests, renal function, cumulative peripheral neuropathy assessment (sensory grading at each cycle)
Handling Protection	Must follow cytotoxic drug handling regulations; reconstitution requires the supplied Cremophor EL–based diluent; personnel protection and closed-system transfer devices recommended

Safety Considerations

Drug Interactions (276 total interactions identified):

Severity	Interacting Drug	Clinical Note
Major	Deferiprone	Additive myelosuppression; concurrent use should be avoided
Major	Samarium (153Sm) lexidronam	Additive bone marrow suppression risk
Moderate	Clarithromycin	CYP3A4 inhibitor; may increase ixabepilone plasma exposure and toxicity
Moderate	Cobicistat	Strong CYP3A4 inhibitor; dose adjustment may be required
Moderate	Aprepitant	Mixed CYP3A4 modulator; monitor for altered ixabepilone levels
Moderate	Dexamethasone	CYP3A4 inducer; may reduce ixabepilone efficacy
Moderate	Miconazole / Clotrimazole	Azole antifungals inhibit CYP3A4; increased toxicity risk
Moderate	Rosuvastatin / Simvastatin	Potential additive hepatotoxicity; monitor liver enzymes
Moderate	Palifermin	Timing restriction — palifermin should not be administered within 24 hours before/after cytotoxic chemotherapy

Additional Safety Note: Peripheral neuropathy (predominantly sensory, cumulative) is a class effect of ixabepilone across Phase II/III studies. It is usually mild to moderate in severity and similar in profile to taxane-induced neuropathy.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A completed, enrollment-adequate Phase II trial (NCT00331643, n=120) conducted by the Children’s Oncology Group specifically evaluated ixabepilone in pediatric refractory solid tumors including Ewing sarcoma, providing Level L2 evidence. The mechanistic rationale is well-supported: Ewing sarcoma’s low P-glycoprotein expression renders it sensitive to epothilone-class agents, and ixabepilone’s established FDA safety record (breast cancer approval) reduces de-novo safety uncertainty. The drug is not yet registered in India, but the clinical evidence base justifies moving forward under defined safeguards.

To proceed, the following is needed:

Critical: Full analysis of PMID 20068084 to extract the response rate, progression-free survival, and OS data specifically for the Ewing sarcoma patient stratum
Critical: CDSCO/TFDA package insert review for complete warnings, contraindications, and dosing — currently a blocking data gap (DG001)
High priority: Detailed MOA data from DrugBank API to complete mechanistic linkage analysis (DG002)
India regulatory pathway assessment: CDSCO IND application or import license required before any local use
Comparison with current standard-of-care regimens for relapsed/refractory Ewing sarcoma (e.g., irinotecan/temozolomide, high-dose chemotherapy) to define positioning
Pediatric peripheral neuropathy monitoring protocol and dose-reduction guidelines for the target population
Assessment of potential combination strategies with standard Ewing sarcoma backbone regimens (e.g., vincristine, ifosfamide, etoposide)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.